Trial Profile
A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects With Chronic HCV Infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Dec 2021
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms POLARIS-1
- Sponsors Gilead Sciences
- 20 Dec 2019 According to an Gilead Sciences media release, the China National Medical Products Administration (NMPA) has approved Vosevi for the treatment of chronic hepatitis C virus (HCV) infection in adults without cirrhosis or with compensated cirrhosis who have failed prior treatment with a direct-acting antiviral (DAA) therapy. The approval of Vosevi in China is supported by POLARIS-1 and POLARIS-4 studies.
- 27 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 01 Oct 2018 Results of a pooled analysis assessing patients reported outcomes from 11 studies, published in the Value in Health.